FDA panel narrowly supports multi-cancer blood test
Medical Xpress1 min read64 words
A blood test designed to detect over 50 types of cancer before symptoms emerge received limited support from U.S. Food and Drug Administration (FDA) advisers on Wednesday. The panel voted in favor of the diagnostic tool, although several members expressed skepticism regarding its effectiveness.
The FDA advisory group’s decision highlights ongoing debate within the medical community about the reliability of early-stage cancer screening methods.
Read the original at Medical Xpress
🤖 AI-generated content — This article was automatically summarised from public RSS feeds by AutoBrief. Verify important information with the original source.